Similar articles for PMID: 34083307

Year	Number of Results
2014	1
2015	9
2016	6
2017	14
2018	19
2019	23
2020	25
2021	22
2022	6
2023	1
2024	0

1

The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab.

Kuramochi H, Yamada T, Yoshida Y, Matsuda A, Kamiyama H, Kosugi C, Ishibashi K, Fukazawa A, Ihara K, Sonoda H, Yoshimatsu K, Yoshida H, Hasegawa S, Sakamoto K, Ishida H, Koda K; TAS CC3 Study Group. Kuramochi H, et al. Anticancer Res. 2021 Jun;41(6):3131-3137. doi: 10.21873/anticanres.15098. Anticancer Res. 2021. PMID: 34083307

2

Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer.

Matsuda A, Yamada T, Matsumoto S, Sakurazawa N, Kawano Y, Shinozuka E, Sekiguchi K, Suzuki H, Yoshida H. Matsuda A, et al. Anticancer Res. 2019 Aug;39(8):4343-4350. doi: 10.21873/anticanres.13602. Anticancer Res. 2019. PMID: 31366528

3

Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.

Dogan E, Bozkurt O, Sakalar T, Derin S, Inanc M, Ozkan M. Dogan E, et al. J BUON. 2019 Sep-Oct;24(5):1861-1869. J BUON. 2019. PMID: 31786848 Free article.

4

Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.

Ishizaki T, Mazaki J, Enomoto M, Shigoka M, Kasahara K, Matsudo T, Kawakita H, Nagakawa Y, Katsumata K, Tsuchida A. Ishizaki T, et al. Anticancer Res. 2021 Apr;41(4):2157-2163. doi: 10.21873/anticanres.14988. Anticancer Res. 2021. PMID: 33813427 Clinical Trial.

5

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.

Kotani D, Kuboki Y, Horasawa S, Kaneko A, Nakamura Y, Kawazoe A, Bando H, Taniguchi H, Shitara K, Kojima T, Tsuji A, Yoshino T. Kotani D, et al. BMC Cancer. 2019 Dec 27;19(1):1253. doi: 10.1186/s12885-019-6475-6. BMC Cancer. 2019. PMID: 31881856 Free PMC article. Clinical Trial.

6

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.

Pfeiffer P, Yilmaz M, Möller S, Zitnjak D, Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG, Qvortrup C. Pfeiffer P, et al. Lancet Oncol. 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27. Lancet Oncol. 2020. PMID: 31999946 Clinical Trial.

7

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K. Fujii H, et al. Oncologist. 2020 Mar;25(3):e469-e476. doi: 10.1634/theoncologist.2019-0541. Epub 2019 Nov 20. Oncologist. 2020. PMID: 32162797 Free PMC article.

8

Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.

Yang J, Guo X, Wang M, Ma X, Ye X, Lin P. Yang J, et al. Sci Rep. 2017 Dec 7;7(1):17166. doi: 10.1038/s41598-017-17130-6. Sci Rep. 2017. PMID: 29215037 Free PMC article.

9

Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.

Cruz-Ramos M, Del Puerto-Nevado L, Zheng B, López-Bajo R, Cebrian A, Rodríguez-Remirez M, García-García L, Solanes-Casado S, García-Foncillas J. Cruz-Ramos M, et al. J Geriatr Oncol. 2019 Sep;10(5):742-748. doi: 10.1016/j.jgo.2018.10.002. Epub 2018 Oct 13. J Geriatr Oncol. 2019. PMID: 30327283

10

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V, Salvatore L, Borelli B, Pietrantonio F, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ. Suenaga M, et al. Eur J Cancer. 2017 Nov;86:197-206. doi: 10.1016/j.ejca.2017.08.033. Epub 2017 Oct 6. Eur J Cancer. 2017. PMID: 28992563 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

112 results

Results by year